Literature DB >> 6302703

Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells.

M Rabson, L Heston, G Miller.   

Abstract

Early antigens (EAs) are made when the P3J-HR-1 strain of Epstein-Barr virus (EBV) infects cells that already harbor latent EB viral genomes. We wished to identify EBV genes that might participate in induction of EAs. We have recently isolated from the HR-1 line EB viral variants that are unable to induce EAs. We have now isolated a clone of HR-1 cells that releases virus with the capacity to induce EA. We compared the genome of the EB variant that possesses the capacity to induce EA with that of a variant that is unable to induce EA and with parental stock that was the source of both different biotypes of EBV. The variant that is able to induce EA contains, in molar or greater quantities, additional fragments of EBV DNA not found in the variant that lacks that capacity. These same DNA fragments are present in submolar quantities in the parental DNA, indicating that they represent a subpopulation in the parental viral DNA mixture. We thus provide evidence that EA induction is brought about by unusual forms of EBV DNA that are likely to act by regulating expression of the genome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6302703      PMCID: PMC393908          DOI: 10.1073/pnas.80.9.2762

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction.

Authors:  J Menezes; W Leibold; G Klein
Journal:  Exp Cell Res       Date:  1975-05       Impact factor: 3.905

2.  Anatomy of herpes simplex virus DNA. III. Characterization of defective DNA molecules and biological properties of virus populations containing them.

Authors:  N Frenkel; R J Jacob; R W Honess; G S Hayward; H Locker; B Roizman
Journal:  J Virol       Date:  1975-07       Impact factor: 5.103

3.  Nucleic acid renaturation and restriction endonuclease cleavage analyses show that the DNAs of a transforming and a nontransforming strain of Epstein-Barr virus share approximately 90% of their nucleotide sequences.

Authors:  B Sugden; W C Summers; G Klein
Journal:  J Virol       Date:  1976-05       Impact factor: 5.103

4.  Heterogeneity of Epstein-Barr virus originating from P3HR-1 cells. I. Studies on EBNA induction.

Authors:  K O Fresen; B Merkt; G W Bornkamm; H Hausen
Journal:  Int J Cancer       Date:  1977-03-15       Impact factor: 7.396

5.  Transforming activity of Epstein-Barr virus obtained by superinfection of Raji cells.

Authors:  Y Yajima; B Marczynska; M Nonoyama
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

6.  Persisting oncogenic herpesvirus induced by the tumour promotor TPA.

Authors:  H zur Hausen; F J O'Neill; U K Freese; E Hecker
Journal:  Nature       Date:  1978-03-23       Impact factor: 49.962

7.  Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye.

Authors:  M Rabson; L Gradoville; L Heston; G Miller
Journal:  J Virol       Date:  1982-12       Impact factor: 5.103

8.  Clonal transformation of adult human leukocytes by Epstein-Barr virus.

Authors:  B Sugden; W Mark
Journal:  J Virol       Date:  1977-09       Impact factor: 5.103

9.  Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference.

Authors:  G Miller; J Robinson; L Heston; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

10.  Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.

Authors:  Y Hinuma; M Konn; J Yamaguchi; D J Wudarski; J R Blakeslee; J T Grace
Journal:  J Virol       Date:  1967-10       Impact factor: 5.103

View more
  67 in total

1.  Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites.

Authors:  T Ragoczy; G Miller
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Marked variation in the size of genomic plasmids among members of a family of related Epstein-Barr viruses.

Authors:  J L Kolman; C J Kolman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

3.  Epstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants.

Authors:  A Marchini; R Longnecker; E Kieff
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

4.  Growth of B95-8 cells and expression of Epstein-Barr virus lytic phase in serum-free medium.

Authors:  J E Shaw; R G Petit; K Leung
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

Review 5.  Epstein-Barr virus infection at mucosal surfaces: detection of genomic variants with altered pathogenic potential.

Authors:  J W Sixbey; P Shirley
Journal:  Springer Semin Immunopathol       Date:  1991

6.  Mapping of genes in BamHI fragment M of Epstein-Barr virus DNA that may determine the fate of viral infection.

Authors:  J Sample; G Lancz; M Nonoyama
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

7.  Sequences adjacent to oriP improve the persistence of Epstein-Barr virus-based episomes in B cells.

Authors:  R E White; R Wade-Martins; M R James
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Immortalization of human primary B lymphocytes in vitro with DNA.

Authors:  B Kempkes; D Pich; R Zeidler; W Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

9.  Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.

Authors:  F Wang; S F Tsang; M G Kurilla; J I Cohen; E Kieff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

10.  Points of recombination in Epstein-Barr virus (EBV) strain P3HR-1-derived heterogeneous DNA as indexes to EBV DNA recombinogenic events in vivo.

Authors:  Kazufumi Ikuta; Shamala K Srinivas; Tim Schacker; Jun-ichi Miyagi; Rona S Scott; John W Sixbey
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.